Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases
Hakim, E., Mostafa, A., Mohamed, M., Sherif, M., El Naggar, M. (2022). Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases. EKB Journal Management System, 18(2), 45-51. doi: 10.21608/resoncol.2022.135734.1166
Elia F. Hakim; Amina M. Mostafa; Mohamed A. H. Mohamed; Mahmoud F. A. Sherif; Maha S. El Naggar. "Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases". EKB Journal Management System, 18, 2, 2022, 45-51. doi: 10.21608/resoncol.2022.135734.1166
Hakim, E., Mostafa, A., Mohamed, M., Sherif, M., El Naggar, M. (2022). 'Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases', EKB Journal Management System, 18(2), pp. 45-51. doi: 10.21608/resoncol.2022.135734.1166
Hakim, E., Mostafa, A., Mohamed, M., Sherif, M., El Naggar, M. Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases. EKB Journal Management System, 2022; 18(2): 45-51. doi: 10.21608/resoncol.2022.135734.1166

Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases

Research in Oncology
Article 1, Volume 18, Issue 2, December 2022, Page 45-51  XML PDF (390.25 K)
Document Type: Original Article
DOI: 10.21608/resoncol.2022.135734.1166
View on SCiNiTO View on SCiNiTO
Authors
Elia F. Hakim email 1; Amina M. Mostafa2; Mohamed A. H. Mohamed2; Mahmoud F. A. Sherif3; Maha S. El Naggar2
1Department of Clinical Oncology, Sohag Cancer Center, Sohag, Egypt
2Department of Clinical Oncology, Assuit University, Assuit, Egypt
3Department of Pathology, Assuit University, Assuit, Egypt
Abstract
Background: Tumor-infiltrating lymphocytes (TILs) were found to be associated with a better clinical outcome in specific subtypes of breast cancer.
Aim: To study the association between TILs and the prognosis of Egyptian patients with HER2-negative breast cancer metastatic to the viscera.
Methods: This prospective study included 100 patients with HER2-negative metastatic breast cancer. Intratumoral TILs, stromal TILs, and CD4 and CD8 were examined in the pathological specimens and their relationship with survival and response to treatment was studied.
Results: At a median follow-up period of 43 months, the median overall survival was 44.7 months (95%CI: 39.2-50.2) and the 5-year overall survival rate was 28%. A high level of CD8+ve TILs was associated with significantly longer overall survival (p < 0.001) and progression-free survival (p=0.043). There was no significant correlation between intratumoral TILs, stromal TILs, or CD4+ve and overall survival.
Conclusions: A higher level of CD8+ve TILs is associated with better overall as well as progression-free survival in HER2-negative breast cancer with visceral metastases.
Keywords
Breast cancer; CD4; CD8; HER2; Prognosis; Tumor-infiltrating lymphocytes; Visceral metastases
Statistics
Article View: 490
PDF Download: 544